* Drug to be used in patients with advanced cancer
* EU updates guidelines for drug as second-line therapy
ZURICH, Aug 6 (Reuters) - Swiss drugmaker Novartis AG NOVN.VX said on Thursday the EU had approved Afinitor for the treatment of patients with advanced kidney cancer.
The drug will be used on patients whose disease progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy, which cuts off blood supply to cancers.
Several European treatment guidelines have been updated to recommend Afinitor as a second-line advanced kidney cancer therapy after progression on targeted therapies, Novartis said.
U.S. regulators approved Afinitor for use in advanced kidney cancer in March. [ID:nLU719128]
Afinitor, which works by blocking a protein known as mTOR and disrupting the growth, division and metabolism of cancer cells is a vital part of Novartis’s expansion in cancer drugs.
Novartis is keen to extend its use into treating other types of cancer and expects to file for use in neuroendocrine tumours within the next year.
Reporting by Jason Rhodes; editing by John Stonestreet